- United States
- /
- Life Sciences
- /
- NasdaqGM:TKNO
Alpha Teknova, Inc. (NASDAQ:TKNO) Just Reported, And Analysts Assigned A US$23.00 Price Target
As you might know, Alpha Teknova, Inc. (NASDAQ:TKNO) just kicked off its latest quarterly results with some very strong numbers. Results overall were credible, with revenues arriving 6.2% better than analyst forecasts at US$11m. Higher revenues also resulted in lower statutory losses, which were US$0.20 per share, some 6.2% smaller than the analysts expected. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. We thought readers would find it interesting to see the analysts latest (statutory) post-earnings forecasts for next year.
See our latest analysis for Alpha Teknova
Taking into account the latest results, the most recent consensus for Alpha Teknova from three analysts is for revenues of US$47.2m in 2022 which, if met, would be a sizeable 21% increase on its sales over the past 12 months. Per-share losses are expected to explode, reaching US$1.05 per share. Before this earnings announcement, the analysts had been modelling revenues of US$46.3m and losses of US$1.09 per share in 2022. So there seems to have been a moderate uplift in analyst sentiment with the latest consensus release, given the upgrade to loss per share forecasts for this year.
Even with the lower forecast losses, the analysts lowered their valuations, with the average price target falling 18% to US$23.00. It looks likethe analysts have become less optimistic about the overall business. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. There are some variant perceptions on Alpha Teknova, with the most bullish analyst valuing it at US$26.00 and the most bearish at US$20.00 per share. Even so, with a relatively close grouping of estimates, it looks like the analysts are quite confident in their valuations, suggesting Alpha Teknova is an easy business to forecast or the the analysts are all using similar assumptions.
These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Alpha Teknova's past performance and to peers in the same industry. It's clear from the latest estimates that Alpha Teknova's rate of growth is expected to accelerate meaningfully, with the forecast 29% annualised revenue growth to the end of 2022 noticeably faster than its historical growth of 14% over the past year. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 8.0% per year. Factoring in the forecast acceleration in revenue, it's pretty clear that Alpha Teknova is expected to grow much faster than its industry.
The Bottom Line
The most obvious conclusion is that the analysts made no changes to their forecasts for a loss next year. Happily, there were no major changes to revenue forecasts, with the business still expected to grow faster than the wider industry. The consensus price target fell measurably, with the analysts seemingly not reassured by the latest results, leading to a lower estimate of Alpha Teknova's future valuation.
With that in mind, we wouldn't be too quick to come to a conclusion on Alpha Teknova. Long-term earnings power is much more important than next year's profits. We have forecasts for Alpha Teknova going out to 2024, and you can see them free on our platform here.
Even so, be aware that Alpha Teknova is showing 2 warning signs in our investment analysis , you should know about...
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NasdaqGM:TKNO
Alpha Teknova
Produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally.
Excellent balance sheet low.